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Abstract		We	consider	the	problem	of	selecting	the	optimal	subgroup	to	treat	when	data	on	covariates	is	available	from	a	randomized	trial	or	observational	study.	We	distinguish	between	four	different	settings	including	(i)	treatment	selection	when	resources	are	constrained,	(ii)	treatment	selection	when	resources	are	not	constrained,	(iii)	treatment	selection	in	the	presence	of	side	effects	and	costs,	and	(iv)	treatment	selection	to	maximize	effect	heterogeneity.	We	show	that,	in	each	of	these	cases,	the	optimal	treatment	selection	rule	involves	treating	those	for	whom	the	predicted	mean	difference	in	outcomes	comparing	those	with	versus	without	treatment,	conditional	on	covariates,	exceeds	a	certain	threshold.	The	threshold	varies	across	these	four	scenarios	but	the	form	of	the	optimal	treatment	selection	rule	does	not.	The	results	suggest	a	move	away	from	traditional	subgroup	analysis	for	personalized	medicine.	New	randomized	trial	designs	are	proposed	so	as	to	implement	and	make	use	of	optimal	treatment	selection	rules	in	health	care	practice.				
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Introduction		Biomedical	researchers	and	social	scientists	are	often	interested	in	identifying	the	subgroups	that	would	benefit	most	from	a	particular	treatment	or	intervention.	In	randomized	trials,	subgroup	analyses	are	often	used	to	compare	the	effect	of	treatment	across	subgroups	defined	by	various	pre-treatment	covariates	(Yusuf	et	al.,	1991;	Assmann	et	al.,	2000;	Pocock	et	al,	2002;	Rothwell,	2005;	Lagakos,	2006;	Wang	et	al.,	2007).	Such	analyses	can	help	give	insight	into	whether	a	treatment	might	be	more	effective	for	men	versus	women,	or	for	younger	versus	older	persons,	or	for	any	other	characteristic	or	variable	defined	prior	to	receipt	of	treatment.	These	types	of	analyses	are	relevant	if	the	effect	of	treatment	might	vary	across	individuals	in	a	population,	a	phenomenon	often	referred	to	as	“effect	heterogeneity.”	Such	analyses	can	be	useful	in	deciding	who	to	treat,	or	who	to	treat	first,	if	resources	are	limited.	They	can	also	be	useful	when	deciding	which	of	two	treatments	to	give	to	whom.			While	well-established	methodology	has	been	used	for	decades	to	carry	out	such	subgroup	analyses	across	strata	defined	by	a	single	covariate	(Rothman	et	al.,	1980;	Rothman,	1986;	Yusuf	et	al.,	1991;	Hosemer	and	Lemeshow,	1992;	Li	and	Chambless,	2007;	VanderWeele	and	Knol,	2014),	in	actual	practice	it	would	be	more	desirable	to	make	use	of	data	on	numerous	covariates.	Viewed	from	the	individual	perspective,	we	are	interested	in	knowing	how	to	best	choose	the	appropriate	treatment	for	an	individual	with	a	particular	set	of	characteristics.	This	task	is	sometimes	now	described	as	“personalized	medicine”	or	“precision	medicine.”	It	is	the	optimal	selection	of	treatment	for	the	individual	(Murphy,	2003;	Robins,	2004;	Chakraborty	and	Moodie,	2013).	However,	viewed	from	the	perspective	of	a	population,	if	we	optimize	the	treatment	for	each	individual,	we	are	also	optimizing	the	outcomes	for	the	population	and	are	thus	interested	in	which	subgroups	to	give	which	treatment	in	order	to	maximize	the	outcomes	within	a	population	of	interest,	possibly	subject	to	resource	constraints.		To	make	progress	with	multiple	covariates	for	this	task,	it	is	not	uncommon	in	the	biomedical	or	social	sciences	to	form	a	“prognostic	score”	(Rothwell,	1995;	Hayward	et	al.,	2006;	Kent	and	Hayward,	2007;	Pocock	and	Lubsen,	2008;	Abadie	et	al.,	2013).	In	a	randomized	trial	with	treatment	and	control,	this	prognostic	score	is	defined	as	the	predicted	value	of	the	outcome,	conditional	on	an	individual’s	covariates,	if	that	person	were	not	given	treatment.		The	prognostic	score	is	often	obtained	by	first	fitting	a	regression	model	of	the	outcome	on	the	pre-treatment	covariates	among	the	control	arm	of	the	randomized	trial.	Using	the	estimates	of	the	regression	parameters	of	this	model,	one	can	then	obtain	predicted	outcomes	under	the	absence	of	treatment	for	each	individual	in	the	study	to	give	the	prognostic	score.	The	prognostic	score	itself	is	then	typically	taken	as	the	variable	by	which	subgroups	are	formed.	An	analyst	might	for	example,	subsequently	analyze	the	data	within	tertiles,	quartiles,	or	quintiles	of	the	prognostic	score.	If	those	with	low	prognostic	scores	would	benefit	most	from	treatment	then	this	might	be	the	group	for	which	it	would	be	best	to	target	treatment.	This	approach	is	used	with	some	
frequency	in	the	biomedical	and	social	sciences	(Kent	et	al.,	2002;	Fox	et	al.,	2005;	Rothwell	et	al.,	2005;	Abadie	et	al.,	2013;	Pane	et	al.,	2014).	It	is	sometimes	also	referred	to	as	“risk	stratification”	(Kent	and	Hayward,	2007)	or	“endogenous	stratification”	(Abadie	et	al.,	2013).	While	such	procedures	theoretically	are	effective	with	very	large	sample	sizes,	recent	evidence	suggests	that	in	most	practical	settings,	even	with	thousands	of	study	participants	(Abadie	et	al.,	2013),	biases	from	this	sort	of	approach	result	from	overfitting	if	the	same	data	are	used	to	form	the	prognostic	score	and	to	run	the	subgroup	analyses	(Peck,	2003;	Hansen,	2008;	Abadie	et	al.,	2013).		Various	techniques,	using	cross-validiation,	have	been	proposed	to	address	these	biases	(Abadie	et	al.,	2013).		However,	a	more	fundamental	problem	with	the	approach	is	that	even	if	such	biases	were	absent,	using	the	prognostic	score	or	individual-covariate	subgroup	analysis,	does	not	in	fact	identify	the	optimal	treatment	allocation	rule.	There	are	better	ways	to	use	the	covariate	data	available	to	optimize	an	individual’s	outcome	and	the	mean	outcomes	for	the	population.	A	growing	literature	has	begun	to	explore	statistical	approaches	for	more	effective	treatment	selection	rules	(Cai	et	al.,	2011;	Zhao	et	al.,	2013;	Luedtke	and	van	der	Laan,	2015,	2016ab).	In	fact,	what	such	an	optimal	rule	depends	subtly	on	precisely	what	question	the	analysis	is	intended	to	address.		In	this	paper	we	will	present	four	settings	in	which	optimal	subgroup	selection	is	of	interest.	We	will	describe	these	settings	and	the	optimal	treatment	rule	in	each.	We	will	discuss	how	the	approaches	in	this	paper	relate	to	what	is	typically	done	in	practice	and	how	might	be	best	to	proceed	in	subsequent	research	when	selecting	optimal	subgroups	for	treatment	is	of	interest.	New	randomized	trial	designs	are	further	proposed	so	as	to	implement	and	make	use	of	optimal	treatment	selection	rules	in	practice.			
Notation		We	will	let	A	denote	a	treatment	or	intervention	under	study.	We	will	assume	that	receipt	of	treatment	has	been	randomized	with	probability	1/2	but	we	will	comment	later	in	the	paper	on	how	the	methodology	described	here	is	also	potentially	applicable	to	observational	studies.	We	will	let	Y	denote	an	outcome	of	interest.	Finally	we	will	let	C	denote	a	set	of	pre-treatment	covariates	that	are	available	for	each	individual	in	the	study.	We	will	let	Y1	denote	the	potential	outcome	(Rubin,	1974)	that	would	have	occurred	for	each	individual	if	they	had	received	treatment	and	we	will	let	Y0	denote	the	potential	outcome	that	would	have	occurred	under	control.	We	only	get	to	observe	one	of	Y1	and	Y0:	we	observe	Y1	for	those	who	actually	received	treatment	and	Y0	for	those	who	were	actually	in	the	control	arm.	We	do	not	in	general	know	the	potential	outcome	if	an	individual	had	been	in	the	other	arm	of	the	trial.			In	what	follows,	the	task	of	treatment	selection	will	essentially	be	to	partition	the	population	into	two	groups,	which	we	will	call	“T”	and	“S”,	those	receiving	the	
treatment,	and	those	not	receiving	the	treatment,	respectively.	The	goal	will	be,	in	each	setting,	to	decide	on	how	to	partition	the	population	into	those	who	do	versus	do	not	receive	treatment	in	order	to	maximize	mean	outcomes.	We	will	refer	to	this	partition	of	individuals	who	do	and	do	not	receive	treatment	as	the	optimal	treatment	rule.		We	will,	for	simplicity,	here	assume	that	treatment	A	is	binary	with	1	denoting	treatment	and	0	denoting	control.	However,	the	ideas	that	are	developed	below	are	also	applicable	if	we	are	comparing	two	different	treatments	so	that	A=1	denotes	one	treatment	and	A=0	denotes	another.	Although	we	will	generally	use	of	“treatment”	and	“control”,	the	same	methods	and	ideas	described	below	are	applicable	also	in	the	setting	of	comparing	two	treatments	with	“selecting	who	gets	treatment”	simply	interpreted	as	“selecting	who	gets	the	first	treatment”	and	“control”	interpreted	as	“those	receiving	the	second	treatment.”	In	the	discussion	section	we	will	also	comment	on	how	the	ideas	potentially	extend	to	settings	when	more	than	two	treatments	are	being	considered.			In	what	follows	we	will	provide	an	overview	of	the	relevant	concepts	and	methods.	We	will	state	results	that	are	precise	under	some	technical	conditions.	More	formal	statements	and	proofs	are	given	in	the	Online	Appendix	and	elsewhere	(Luetke	and	van	der	Laan,	2015,	2016ab).			
Four	Questions	Relevant	to	Optimal	Subgroup	Selection		We	will	consider	four	settings	that	may	be	of	interest	in	selecting	optimal	subgroups	for	treatment.	Stated	intuitively,	these	settings	are:		 1. Who	do	we	treat	if	resources	are	limited	so	that	we	can	only	treat	q%	of	the	population?	2. Who	do	we	treat	if	resources	are	not	limited	so	that	we	could	potentially	treat	everyone	and	are	simply	deciding	who	would	benefit	from	treatment?	3. Who	do	we	treat	if	resources	are	not	limited,	but	are	subject	to	costs	or	side	effects?	4. How	do	we	select	subgroups	to	maximize	the	“effect	heterogeneity”	across	subgroups?			We	will	address	each	question	in	turn.			
Setting	1.	Subgroup	selection	under	resource	constraints		First	let	us	suppose	that	due	to	some	form	of	resource	constraints	(e.g.	costs,	doses	available,	etc.),	we	are	only	able	to	treat	at	most	q%	of	the	population.	We	have	data	from	a	randomized	trial	of	treatment	A	where	we	have	collected	outcome	Y	and	pretreatment	covariates	C.	We	want	to	use	the	covariates	C,	and	the	outcome	data	from	our	randomized	trial	to	determine	a	treatment	rule	in	order	to	partition	the	
population	into	those	that	we	should	treat	so	as	to	maximize	the	expected	outcome	for	the	population,	subject	to	the	constraint	that	we	can	only	treat	q%	of	the	population.	Once	we	decide	on	these	two	sets,	T,	the	treated,	and	S,	the	untreated,	then	the	expected	outcome	for	the	population	under	this	treatment	rule	is:		 !"##E[Y|A=1,T]	+	(1- !"##)E[Y|A=0,S]	 	 	 	 	 (1)		In	other	words,	for	q%	of	the	population	we	get	the	average	outcome	under	treatment	for	the	subgroup	T	that	we	selected	for	treatment	and	for	(100-q)%	of	the	population	we	get	the	average	outcome	under	control	for	the	subgroup	S	that	we	selected	not	to	receive	treatment.		It	is	shown	in	the	eAppendix	that	if	we	knew	the	potential	outcomes,	Y1	and	Y0,	for	each	individual	in	the	population	then	the	optimal	treatment	rule	to	maximize	the	expected	outcome	for	the	population	would	simply	be	to	treat	those	for	whom	{Y1-Y0>k}	where	k	is	determined	so	that	exactly	q%	are	treated.	In	other	words,	if	we	knew	the	potential	outcomes	for	each	individual,	so	that	we	knew	the	actual	effect,	Y1-Y0,	of	treatment	for	each	individual,	we	would	simply	treat	the	q%	for	which	the	effect	of	treatment	itself	was	largest.	In	actual	fact	however,	we	do	not	know	both	potential	outcomes	for	every	individual	in	the	population.	We	only	have	our	randomized	trial	data,	our	outcomes	Y,	and	our	covariates	C.	So	we	want	to	use	C	to	partition	individuals	into	those	who	we	do	or	do	not	treat	to	maximize	outcomes.	It	is	again	shown	in	the	eAppendix	that	to	maximize	outcomes,	using	covariates	C,	the	optimal	treatment	rule	is	to	treat	those	with	covariate	values	c	such	that			{E[Y|A=1,C=c]-E[Y|A=0,C=c]>k}			where	the	cut-off	k	is	again	determined	so	that	exactly	q%	are	treated.	In	other	words,	the	optimal	treatment	rule	is	to	treat	the	q%	with	the	highest	expected	treatment	effect	conditional	on	their	covariates.	The	expected	treatment	effect	for	each	individual	conditional	on	their	covariates	is	something	that	can	be	estimated	from	the	data	in	a	randomized	trial	and	thus	this	treatment	rule	can	be	implemented	in	practice.	We	could,	for	example,	fit	regression	models	for	the	expected	outcome	under	treatment	E[Y|A=1,C=c]	and	under	control	E[Y|A=0,C=c],	(or,	more	directly,	their	difference)	conditional	on	covariates,	to	obtain	estimates.	In	the	next	section,	we	will	discuss	some	statistical	issues	relevant	to	implementing	this	in	practice.	However,	again,	it	can	be	shown,	that	the	best	we	can	do	in	terms	of	maximizing	outcomes	for	the	population	using	just	the	covariates	C	is	to	treat	those	with	the	highest	expected	treatment	effect,	E[Y|A=1,C=c]-E[Y|A=0,C=c],	conditional	on	their	covariates.	With	this	treatment	rule	the	expected	outcome	for	the	population	is	again	then	qE[Y|A=1,T]	+	(1-q)E[Y|A=0,S].		The	expected	outcome	under	the	treatment	rule	will	not	be	as	high	as	we	could	have	obtained	had	we	known	both	potential	outcomes	for	all	individuals,	but	again	this	is	the	best	we	can	do	with	the	measured	covariates	C.	We	could	compare	the	expected	
outcome	(1)	under	the	treatment	rule	to	what	we	would	obtain	if	we	simply	randomly	selected	q%	of	the	population	for	treatment,	in	which	case	we	would	have	an	expected	outcome	of:		 !"##E[Y|A=1]	+	(1- !"##)E[Y|A=0]	 	 	 	 	 	 	 (2)		How	much	better	we	do	under	the	treatment	rule	using	the	covariates	C	will	depend	in	part	on	how	predictive	the	measured	covariates	are	of	the	association	between	treatment	and	the	outcome	of	interest,	and	also	how	well	we	statistically	model	the	expected	outcomes	E[Y|A=1,C=c]	and	E[Y|A=0,C=c],	or,	more	directly,	their	difference.	We	could	compare	the	expected	population	outcomes	in	(1)	under	different	estimates	of	the	optimal	treatment	rule	using	different	modeling	techniques.	Again,	in	the	next	section	we	will	consider	issues	of	statistical	modeling.	Intuitively,	how	well	we	improve	on	the	outcomes	by	selecting	subgroups	for	treatment	using	covariates	C,	instead	of	randomly	allocating	treatment,	will	effectively	depend	on	how	well	we	can	use	the	covariates	C	and	statistical	modeling	to	predict	the	potential	outcomes.	i.e.	how	well	we	estimate	the	true	E[Y|A=1,C]-E[Y|A=0,C].			
Setting	2.	Subgroup	selection	under	unconstrained	resources		We	will	now	turn	to	a	different	setting	in	which	resources	are	not	constrained	so	that	we	could	potentially	treat	anyone	who	might	benefit	from	treatment.	Once	again	our	objective	is	to	determine	the	treatment	rule	that	partitions	individuals	into	two	sets:	T,	those	who	do	receive	treatment,	and	S,	those	who	do	not;	so	as	to	maximize	the	average	outcome	for	the	population,	which	is	then:		E[Y|A=1,T]P(T)	+	E[Y|A=0,S]P(S)	 	 	 	 	 	 (3)		It	is	shown	in	the	eAppendix	that	if	we	knew	the	potential	outcomes,	Y1	and	Y0,	for	each	individual	in	the	population	then	the	optimal	treatment	rule	to	maximize	the	expected	outcome	for	the	population	would	simply	be	treat	those	for	whom	{Y1-Y0>0}.	In	other	words,	if	we	knew	the	potential	outcomes	for	each	individual,	we	would	simply	treat	those	for	whom	the	effect	of	treatment	itself	was	positive.	This	is,	of	course,	relatively	intuitive.	In	actual	fact,	we	do	not,	of	course,	know	both	potential	outcomes	for	every	individual;	we	only	have	our	covariates	C.	With	covariates	C,	it	shown	in	the	eAppendix	that	to	maximize	outcomes,	using	covariates	C,	the	optimal	treatment	rule	is	to	treat	those	with	covariate	values	c	such	that			{E[Y|A=1,C=c]-E[Y|A=0,C=c]>0}		 	 	 	 	 	 (4)		In	other	words,	we	treat	those	who	have,	conditional	on	their	covariates,	a	positive	expected	treatment	effect.	We	can	again	estimate	this	from	the	data	from	our	randomized	trial	and	statistical	aspects	of	such	estimation	are	again	briefly	noted	in	
the	next	section.	Under	this	treatment	rule,	the	expected	outcome	will	simply	be	E[Y|A=1,T]P(T)	+	E[Y|A=0,S]P(S).	We	could	compare	this	expected	outcome	under	the	optimal	treatment	rule,	to	the	expected	outcome	if	we	treated	everyone	in	the	population,	E[Y|A=1],	or	if	we	treated	no	one,	E[Y|A=0].	The	extent	to	which	we	can	maximize	the	outcome	using	covariates	C	will	again	depend	in	part	on	how	predictive	the	covariates	C	are	of	the	outcome	of	interest,	and	also	how	well	we	statistically	model	the	expected	outcomes	E[Y|A=1,C=c]	and	E[Y|A=0,C=c],	i.e.	on	how	well	we	can	use	the	covariates	C	and	statistical	modeling	to	predict	the	potential	outcomes.			An	interesting	feature	of	this	second	setting	of	unconstrained	optimal	treatment	selection	is	that	the	tasks	of	individual	decision-making	and	maximizing	population	outcomes	in	fact	coincide.	The	approach	to	maximize	population	outcomes	is	simply	to	assign	treatment	to	anyone	who	would	benefit	from	it.	The	perspectives	of	the	individual	and	the	policy-maker	coincide.	This	was	not	the	case	in	the	first	setting	wherein	an	individual	might	have	a	positive	expected	treatment	effect	and	therefore,	from	an	individual	perspective,	have	expected	benefit	from	treatment,	whereas	a	policy-maker,	to	maximize	population	outcomes,	might	choose	not	to	treat	that	individual	because	others	have	higher	expected	treatment	effects	and	resources	are	limited.			
Setting	3.	Subgroup	selection	under	costs	and	side-effects		Now	let	us	turn	to	a	setting	in	which	resources	are	not	constrained	so	that	we	could	once	again,	in	principle,	treat	everyone	but	now	suppose	the	treatment	itself	has	a	cost	that	we	want	to	take	into	account,	and/or	has	side-effects	that	we	want	to	weigh	against	the	potentially	beneficial	effects	on	our	outcome	of	interest	Y.	Because	of	costs	or	side	effects	we	might,	for	example,	only	want	to	treat	those	with	treatment	effects	larger	than	some	level	d.	Or	more	generally,	that	level	might	depend	on	a	person’s	covariates	c	so	that	we	only	want	to	treat	those	with	treatment	effect	greater	than	some	level	d(c).	The	optimal	rule	(see	eAppendix)	if	we	knew	both	potential	outcomes	for	all	individual	would	then	simply	be	to	treat	those	with	{Y1-Y0>d(c)}	and	the	optimal	rule	with	the	actual	trial	data	and	measured	covariates	C	would	be	to	treat	those	with	{E[Y|A=1,C=c]-E[Y|A=0,C=c]>	d(c)}.	Once	again,	how	well	we	could	optimize	outcomes	would	depend	on	how	predictive	the	covariate	C	were	of	the	association	between	treatment	and	outcome.			
Setting	4.	Maximizing	effect	heterogeneity		When	one	reads	through	the	subgroup	analyses	of	many	randomized	trials,	in	which	subgroup	analyses	are	undertaken	one	covariate	at	a	time,	it	often	seems	that	the	goal	is	to	find	a	covariate,	often	dichotomous	or	dichotomized,	such	that	the	effect	heterogeneity	across	subgroups	defined	by	the	covariate	is	as	large	as	possible.	
When	the	effect	estimate	in	one	subgroup	is	much	larger	than	that	of	the	other,	then	the	subgroup	analysis	is	considered	a	success	and	that	covariate	defining	the	subgroups	is	subsequently	considered	important.	In	fact,	we	could	carry	out	a	similar	exercise	using	data	on	multiple	covariates.	In	this	case,	we	would	want	to	use	covariates	C	to	partition	the	population	into	two	subsets,	T	and	S,	such	that	the	effect	in	the	subgroup	T,	E[Y|A=1,T]-E[Y|A=0,T],	was	much	larger	than	the	effect	in	subgroup	S,	E[Y|A=1,S]-E[Y|A=0,S].	In	other	words,	we	would	want	to	maximize	effect	heterogeneity	by	maximizing	the	difference	between	the	effects	in	these	two	subgroups:		E[Y|A=1,T]-E[Y|A=0,T]			-			{E[Y|A=1,S]-E[Y|A=0,S]}		This	is	in	some	sense	a	generalization	of	what	seems	to	be	the	traditional	subgroup	task	but	extended	to	multiple	covariates	simultaneously.	It	is	shown	in	the	eAppendix	that	once	again	the	solution	to	this	maximization	takes	the	form	of	selecting	T	to	be	those	with	an	actual	treatment	effect,	Y1-Y0	(if	the	potential	outcomes	were	known),	or	expected	treatment	effect	conditional	covariates	C,	E[Y|A=1,C=c]-E[Y|A=0,C=c],	above	some	threshold	k’,	where	k’	can	be	determined	numerically	as	described	in	the	eAppendix.	But	once	again,	it	is	the	expected	conditional	treatment	effect,	E[Y|A=1,C=c]-E[Y|A=0,C=c],	that	is	utilized	in	the	criterion	by	which	treatment	decisions	are	to	be	made	in	this	setting	as	well.	Note,	however,	that	although	this	treatment	rule	maximizes	effect	heterogeneity,	the	average	outcome	under	this	treatment	rule	will	generally	be	worse	than	that	selected	by	the	treatment	rule	that	maximizes	the	outcome	itself	as	in	setting	2.	It	is	thus	not	clear	that	this	treatment	rule	that	maximizes	effect	heterogeneity	is	of	particular	use	in	decision-making,	unlike	those	in	contexts	1,	2	and	3	above.	We	will	return	to	this	point	in	the	discussion.			
Extensions	to	Observational	Studies		Our	discussion	thus	far	has	been	within	the	context	of	a	randomized	trial.	However,	as	discussed	further	in	the	eAppendix,	all	of	the	discussion	above	pertains	also	to	optimal	subgroup	selection	and	treatment	decisions	from	data	arising	from	an	observational	study	as	well,	provided	that	the	covariates	C	suffice	to	control	for	confounding	of	the	effect	of	treatment	A	on	outcome	Y,	though	the	formulae	for	the	optimized	outcome	need	to	be	modified	(see	eAppendix).	With	data	from	observational	studies,	an	additional	context	that	may	be	of	interest	is	if,	in	data	from	the	study,	there	are	available	covariates	C	that	suffice	to	control	for	confounding	for	the	effect	of	treatment	A	on	outcomes	Y,	but	if,	when	treatment	decisions	are	made	subsequently,	only	data	on	some	subset	W	of	the	covariates	C	will	be	available.	Methodology	for	this	setting	has	been	developed	and	is	described	elsewhere	(Luedtke	and	van	der	Laan,	2015;	2016ab).				
Statistical	Analysis		In	the	eAppendix	we	describe	methods	and	formal	statistical	inference	for	estimating	the	optimal	treatment	rule	and	the	outcome	under	it,	as	well	as	software	to	do	so.	While	there	are	many	ways	to	go	about	estimation,	the	methods	described	in	the	eAppendix	flexibly	model	the	difference	in	observed	outcomes	across	treatment	groups	conditional	on	the	covariates	and	use	an	ensemble	technique	called	“super-learner”	(van	der	Laan	et	al.,	2007)	that	considers	numerous	different	possible	models	or	algorithms	for	the	conditional	outcome	differences	and	then	weights	these	according	to	their	mean	square	error	predictive	value	using	cross-validation.	Statistical	inference	for	the	optimal	treatment	rule	and	for	the	outcome	under	it	is	challenging	because	the	same	data	are	being	used	to	estimate	the	treatment	rule	and	the	expected	outcome	under	it.	Sample-splitting	can	potentially	be	used	but	is	not	efficient,	and	averaging	across	split	samples	does	not	yield	valid	inference	(van	der	Laan	and	Luetke,	2014).	The	eAppendix	describes	a	cross-validated	targeted	minimum	loss-based	approach	to	estimate	the	optimal	treatment	rule	and	the	outcome	under	it.	While	the	approach	described	in	the	eAppendix	has	some	desirable	theoretical	properties,	considerable	work	remains	to	be	done	in	assessing	the	sample	sizes	that	are	needed	for	these	techniques	to	be	useful	and	how	the	various	methods	that	have	been	proposed	in	the	literature	compare	to	one	another	in	actual	practice.	While	the	theoretical	methodological	development	has	come	a	long	way	in	the	past	decade,	much	remains	to	be	learned	about	the	application	of	these	methods.	Our	focus	in	this	paper	is	on	conceptual	foundations	for	the	various	methods	that	have	been	proposed,	and	the	implications	of	these	conceptual	foundations	for	interaction	and	subgroup	analyses	within	epidemiology,	the	topic	to	which	we	now	turn.			
Discussion		In	this	paper	we	have	shown	that	under	a	wide	range	of	different	goals	and	settings,	including	making	treatment	decisions	with	or	without	resource	constraints,	and	with	or	without	side	effects,	or	even	when	trying	to	maximize	effect	heterogeneity,	the	correct	approach	to	finding	the	optimal	treatment	rule	is	to	estimate	expected	treatment	effects	for	each	individual	conditional	on	the	covariates.	In	each	of	the	settings	described	above,	the	optimal	treatment	rule	involved	treating	those	above	some	threshold	of	the	conditional	expected	treatment	effect.	The	threshold	differed	according	to	whether	there	were	or	were	not	resource	constraints,	or	whether	there	were	or	were	not	costs	or	side	effects,	or	whether	we	wanted	to	maximize	effect	heterogeneity,	but	the	form	of	the	treatment	rule	did	not	vary	across	these	contexts.	In	each	case,	the	form	of	the	optimal	treatment	rule	was	simply	to	treat	those	with	conditional	expected	treatment	effects	above	a	specific	threshold.	This	has	a	number	of	important	implications	for	the	actual	practice	of	subgroup	analysis,	treatment	selection,	precision	medicine,	and	the	modeling	of	interactions.		
One	fundamental	insight	from	our	discussion	above	is	that	for	treatment	selection	and	decisions,	our	discussion	suggests	a	need	to	move	away	from	subgroup	analyses	conducted	one	covariate	at	a	time.	The	problems	with	this	approach	are	numerous.	First,	subgroups	may	come	into	conflict:	if	subgroup	analyses	indicate	that	treatment	A	is	better	for	women	and	treatment	B	is	better	for	men,	and	also	indicate	that	A	is	better	for	aged	and	B	better	for	younger	persons,	and	we	want	make	treatment	decisions	for	a	younger	woman,	the	subgroup	analyses	conflict.	Second,	the	subgroup	analyses	often	fail	to	answer	the	scientific	question	of	interest.	As	they	are	typically	carried	out,	they	tend	to	be	aimed	at	maximizing	effect	heterogeneity,	whereas	what	is	actually	of	interest	is	maximizing	population	outcomes	or	individual	treatment	decision	making.	The	optimal	treatment	rule	for	maximizing	population	outcomes	or	individual	treatment	decision-making	is	not	the	same	as	for	maximizing	effect	heterogeneity.	Finally,	compared	to	individual	covariate	subgroup	analyses,	we	can	in	fact	do	better	at	maximizing	mean	outcomes	by	making	simultaneous	use	of	all	covariates,	rather	than	running	analyses	one	covariate	at	a	time.	It	is	conceivable,	of	course,	that	the	optimal	treatment	selection	in	some	rare	cases	might	involve	only	a	single	dichotomous	covariate,	or	in	some	settings	a	single	dichotomous	covariate	may	constitute	the	decision	to	be	made	(e.g.	resources	are	limited	so	we	can	only	city	1	or	city	2),	but	in	general	the	optimal	decision-making	rule	will	make	fuller	use	of	covariate	data.		The	need	to	move	away	from	one-covariate-at-a-time	approaches	in	optimizing	population	outcomes	or	individual	treatment	decision-making	is	relevant	not	just	to	traditional	subgroup	analyses	when	we	are	looking	at	whether	the	treatment	effect	is	larger	in	one	group	versus	another,	but	this	same	point	is	also	relevant	to	the	analysis	of	so-called	“qualitative”	or	“cross-over”	interactions	(Gail	and	Simon,	1985;	Piantadosi	and	Gail,	1993;	Pan	and	Wolfe,	1997;	Silvapulle,	2001;	Li	and	Chan,	2006),	in	which	the	treatment	has	a	positive	effect	in	one	subgroup	and	a	harmful	effect	in	another.	The	analysis	of	such	cross-over	interactions	is	again	often	done	one	covariate	at	a	time,	but	for	the	purposes	of	decision-making,	it	ought	to	be	done	using	all	available	relevant	covariate	data.	In	actual	fact,	the	methodology	described	in	setting	2	above	is	doing	precisely	that.		A	second	important	implication	of	the	discussion	in	this	paper	is	that,	for	optimizing	population	outcomes	or	individual	treatment	decision	making,	we	should	move	away	from	the	“prognostic	score”,	that	is	often	employed	in	both	the	biomedical	and	social	sciences	(Hayward	et	al.,	2006;	Kent	and	Hayward,	2007;	Fox	et	al.,	2005;	Rothwell	et	al.,	2005;	Abadie	et	al.,	2013;	Pane	et	al.,	2014).	The	practice	of	stratifying	on	prognostic	scores	in	small-	or	medium-	sized	trials	has	numerous	statistical	problems	with	“overfitting”	documented	elsewhere	(Abadie	et	al.,	2013).	At	a	more	fundamental	level,	though,	it	gets	the	objective	wrong	because	the	patients	at	greatest	risk	of	bad	outcomes	in	the	absence	of	treatment	are	not	necessarily	the	same	patients	who	will	profit	most	from	intervention.	While	stratifying	the	results	of	randomized	trials	using	the	predicted	outcome	under	control	can	provide	some	insight	into	who	might	be	considered	to	have	greatest	need	for	treatment,	it	is	not	the	correct	approach	to	optimize	population	outcomes	
or	individual	treatment	decision-making.	To	optimize	population	outcomes	or	individual	treatment	decision-making,	one	stratifies,	not	by	predicted	outcome	under	control,	but	by	the	expected	effect	of	treatment;	that	is,	the	difference	between	the	predicted	outcome	under	treatment	and	the	predicted	outcome	under	control,	conditional	on	covariates.	It	is	this	stratification	that	gives	one	insight	into	optimal	treatment	decisions	either	with	or	without	resource	constraints.		A	third	important	implication,	related	somewhat	to	the	first,	concerns	the	modeling	of	interactions.	In	reading	the	literature,	one	is	often	left	with	the	impression	that	the	principal	goal	of	interaction	analysis	is	to	determine	whether,	in	a	given	statistical	model,	a	product	term	involving	two	variables	is	“statistically	significant”	or	non-zero.	Methodology	to	detect	to	“interactions”	or	non-zero	product	terms	has	become	increasingly	advanced	(e.g.	Moore	et	al.,	2006;	Green	and	Kern,	2012;	Imai	and	Ratkovic,	2013;	Berger	et	al.,	2015).	However,	once	again,	if	the	purpose	of	the	analysis	is	optimizing	population	outcomes	or	individual	decision-making,	the	question	as	to	whether	a	specific	product	term	in	a	particular	statistical	model	is	present	is,	in	fact,	secondary.	All	that	matters	for	the	task	of	optimizing	population	outcomes	or	individual	decision-making	is	having	predictive	covariates	and	having	statistical	models	that	give	good	predictions	of	expected	outcomes	conditional	on	those	covariates.	If	the	product	terms	help	in	a	particular	model,	they	can	be	included;	if	not,	they	can	be	omitted.	In	either	case,	though,	their	presence	or	absence	is	secondary	to	having	a	good	predictive	model	so	as	to	make	optimal	treatment	decisions.	Indeed	using	models	both	with	and	without	product	terms	and,	more	generally,	numerous	models	and	machine	learning	algorithms,	to	generate	predicted	outcomes,	and	possibly	ensemble	methods	to	average	over,	or	choose	among	them,	as	suggested	above,	is	probably	a	preferable	way	to	proceed.		It	might	be	thought	that	subgroup	analyses	one-covariate-at-a-time	or	the	analysis	of	individual	product	terms	in	statistical	models	may	still	be	of	interest	for	the	purposes	of	understanding	or	explanation.	While	this	may	be	true	to	some	degree,	it	is	important	to	clarify	the	goal	of	such	understanding	or	the	form	of	explanation	that	is	in	view.	If	what	is	thought	to	be	of	importance	is	to	understand	which	covariates	in	fact	are	most	relevant	in	decision-making	(e.g.	because	it	was	thought	undesirable	to	measure	all	of	the	covariates	subsequently	in	treatment	decision-making),	then	one	could	instead	consider	the	result	of	optimal	treatment	rules	on	the	maximized	population	outcome	when	only	certain	subsets	of	the	covariates	C	are	considered.	On	the	other	hand,	if	one	simply	wanted	to	assess	which	covariates	in	some	sense	seemed	most	“responsible”	for	the	effect	heterogeneity,	one	might	instead	still	model	the	outcome	with	all	covariates	simultaneously,	and	then	consider,	for	example,	what	a	one-unit	shift	in	any	given	covariate	for	all	individuals	would	have	in	changing	expected	treatment	effects.	In	linear	models	for	the	expected	outcomes	in	each	treatment	arm,	this	would	simply	be	the	difference	between	the	covariate	coefficient	in	the	model	under	treatment	E[Y|A=1,C=c]	and	the	covariate	coefficient	in	the	model	under	control	E[Y|A=0,C=c].	But	the	approach	of	considering	a	one-unit	shift	in	a	particular	covariate	across	all	individual	could	also	be	employed	in	non-linear	models	as	well.	Other	metrics	could	also	potentially	be	developed.	Finally,	
sometimes	analyses	of	interactions	are	undertaken	for	the	purpose	of	understanding	the	joint	effects	of	the	treatment	and	a	particular	covariate,	or	to	gain	mechanistic	insight	(VanderWeele	and	Robins,	2007;	VanderWeele,	2009,	2015).	In	this	case,	it	may	be	appropriate	to	assess	the	joint	effects	of	one	covariate	at	a	time,	but	in	this	case,	if	the	effect	of	the	covariate	is	in	view,	then	confounding	control	must	be	made	for	the	association	between	that	covariate	and	the	outcome	(VanderWeele,	2009;	VanderWeele	and	Knol,	2011;	VanderWeele,	2015)	and	what	additional	variables	are	needed	to	control	for	such	confounding	will	vary	depending	on	which	covariate	is	in	view.	This	is	no	longer	simply	a	question	of	effect	heterogeneity	but	of	joint	effects	(VanderWeele,	2009;	VanderWeele	and	Knol,	2014).	A	model	which	includes	all	of	the	covariates	C	available	will	not	in	general	be	adequate	to	provide	appropriate	control	in	addressing	this	type	of	question	if	the	covariates	themselves	affect	one	another.				Yet	another	argument	that	might	be	put	forward	for	doing	one-by-one	subgroup	analyses	may	involve	trying	to	generate	heuristics.	A	physician	cannot	remember	the	functional	form	of	two	conditional	expectations	but	can	remember	that	treatment	A	is	better	for	women	and	treatment	B	is	better	for	men.	While	such	treatment	heuristics	can	be	of	some	value,	they	can,	as	already	discussed	above,	come	into	conflict	with	one	another.	Moreover,	the	use	of	such	heuristics	in	decision-making	becomes	even	more	complex	when	there	are	more	than	two	potential	options	to	choose	among,	which	brings	us	to	another	topic	of	our	discussion:	extensions	to	multiple	treatments.		The	setting	of	multiple	treatment	options	is	important	in	general	and	especially	so	in	an	era	of	personalized	or	precision	medicine.	Full	discussion	of	the	issue	is	beyond	the	scope	of	the	present	paper,	but	many	of	the	points	discussed	above	do	generalize	to	the	multiple	treatments	setting.	Specifically,	in	the	task	of	optimizing	treatment	decisions	without	resource	constraints,	the	solution	to	maximizing	the	population	outcome,	which	is	itself	identical,	in	this	setting,	to	maximizing	the	outcome	for	each	individual	involves	a	very	similar	form	to	what	has	already	been	discussed	above.	The	optimal	treatment	rule	in	this	setting	with	measured	covariates	C	simply	involves	obtaining	the	expected	outcome	given	an	individual’s	covariates	C	under	each	possible	treatment,	E[Y|A=a,C=c],	a=0,1,2,…,N,	and	then	assigning	to	each	individual	the	treatment	that	gives	the	highest	predicted	outcome.	Likewise,	for	the	same	reasons	as	those	given	above,	in	this	setting,	if	the	goal	is	to	maximize	population	outcomes	or	individual	decision-making,	there	is	little	reason	to	carry	out	one-by-one-covariate	subgroup	analyses	or	to	consider	which	product	terms	in	statistical	models	are	statistically	significant.		Where	then	does	this	leave	us?	If	we	knew	the	exact	form	of	the	expected	outcomes	conditional	on	covariates	E[Y|A=a,C=c]	separately	for	each	treatment	group,	the	problem	would	essentially	be	solved.	We	simply	assign	the	treatment	that	gives	the	highest	predicted	outcome.	The	task	simply	becomes	obtaining	the	most	predictive	covariates	C	and	obtaining	the	predictions.	In	actual	fact,	the	functional	form	of	the	conditional	expected	outcome	is	unknown	and	must	be	estimated	and	this	becomes	
a	difficult	statistical	task.	In	this	paper,	we	have	pointed	out	some	statistical	methodology	and	software	to	carry	this	out	in	some	settings.	However,	again,	important	work	remains	to	be	done	in	determining	at	what	sample	sizes,	and	for	how	many	covariates,	and	for	how	many	treatment	levels	this	is	in	fact	feasible.		In	the	clinical	setting,	one	might	also	wonder	about	the	role	of	expert	judgment.	Are	there	perhaps	aspects	of	a	patient’s	profile	that	are	not,	or	even	cannot	be,	adequately	captured	by	a	variable	that	we	can	use	in	a	statistical	model?	This	of	course	remains	a	possibility.	Are	we	to	abandon	clinical	judgment	and	simply	rely	on	statistical	models	to	make	such	predictions?	Are	we	to	pit	clinical	judgment	and	modeling	against	one	another?	We	would	like	to	close	this	paper	by	attempting	to	tackle	this	question	head	on	with	a	compromise,	to	allow	both	clinical	judgment	and	predictive	models,	by	proposing	a	new	type	of	study	design.		A	possible	design	–	what	we	will	refer	as	an	“Expected	Outcomes	Trial”	–	is	to	first	use	either	prior	randomized	trial	data,	and/or	observational	data,	with	a	relatively	rich	set	of	covariates	C	to	build	models	for	the	expected	outcomes	with	and	without	treatment.	With	such	models,	for	each	study	participant	in	the	Expected	Outcomes	Trial,	the	clinician	(or	patient)	is	randomized	either	to	receive	no	further	information,	or	to	receive	information	on	the	expected	outcome	given	their	covariates	under	each	treatment	scenario.	This	could	include	outcomes	under	multiple	treatment	options.	The	clinician	(or	patient)	then	decides,	based	on	the	information	available	and	their	own	judgments	and	preferences,	which	treatment	to	select.	Outcomes	are	measured	after	a	suitable	follow-up	period	to	determine	whether	the	information	provided	by	the	predictive	outcome	models	is	useful	in	such	decision-making.		A	trial	of	this	sort	will	allow	decision-makers	to	make	use	of	both	individually-oriented	outcome	predictions	under	statistical	models,	and	also	personal	judgments,	in	making	treatment	decisions.	It	would	also	preserve	decision-maker	autonomy,	and	be	more	likely	to	be	palatable	to	clinicians,	and	therefore	more	likely	also	to	be	scalable.	The	trials	themselves	would	determine	the	additional	utility	of	the	information	provided	by	the	predictive	models.	A	variation	that	added	an	additional	arm	in	which	treatment	always	followed	the	predicted	maximum	outcome	could	also	be	used	to	evaluate	the	role	of	clinical	judgement,	whether	beneficial	or	harmful,	above	and	beyond	reliance	on	predicted	probabilities.		We	believe	that	such	trials	will	be	of	use	in	determining	the	utility	of	prediction	models	for	personalized	or	precision	medicine	in	actual	practical	settings.	Moreover,	we	believe	that	careful	thought	as	to	the	what	the	correct	question	is	in	individual	treatment	decision-making,	and	careful	selection	of	the	correct	optimization	question	and	statistical	method	corresponding	to	the	question	of	interest,	will	result	in	better	patient	outcomes.	Current	practices	of	one-covariate-at-a-time	subgroup	analysis,	the	use	of	prognostic	scores,	and	the	detection	of	significant	interactions	are	simply	not	optimal	for	decision-making.			
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eAppendix for Selecting optimal subgroups for
treatment using many covariates
A. The Form of the Optimal Treatment Rule
Notation
LetA denote a binary treatment of interest, Y an outcome and C a set of measured baseline covariates. Let
Y1 and Y0 denote the potential outcomes for each individual under treatment levels 1 and 0 respectively.
Let the population of individuals be denoted by 
. We rst assume treatment A is randomized and
then consider treatment that may arise from an observational study. For simplicity in the next several
section, in order to give intuitive proofs, we will assume a nite population of individuals with no ties
at the cut-o¤ for the optimal treatment rule. See Luedtke and van der Laan (2015, 2016ab) for further
discussion of these cases without these conditions.
Context 1: Treatment Subgroup Selection Under Limited Resources
Suppose that due to limited resources we can only treat 100q% of the population. We will assume that
treatment is benecial for at least 100q% of the population i.e. P (Y1   Y0 > 0) > q. Otherwise, if we
know this in advance, the problem reduces to Context 2 described below. We desire to partition 
 into
sets S and T such that P (! 2 T ) = q so as to maximize the average outcome if all units in T were treated
and all units in S were untreated. In other words, we wish to identify S and T to solve:
argmaxS;T :S[T=
;S\T=;;P (!2T )=q[qE(Y1j! 2 T ) + (1  q)E(Y0j! 2 S)]:
In fact, choosing S and T to maximize the average outcome if all units in T were treated and all units
in S were untreated is equivalent to choosing S and T to maximize the treatment e¤ect heterogeneity
with 100q% in one group, as stated in the following proposition.
Proposition 1. The solution to
argmaxS;T :S[T=
;S\T=;;P (!2T )=q[qE(Y1j! 2 T ) + (1  q)E(Y0j! 2 S)]
is equivalent to the solution to
argmaxS;T :S[T=
;S\T=;;P (!2T )=q[E(Y1   Y0j! 2 T )  E(Y1   Y0j! 2 S)]:
Proof. We have that
argmaxS;T :S[T=
;S\T=;;P (!2T )=q[E(Y1   Y0j! 2 T )  E(Y1   Y0j! 2 S)]
= argmaxS;T :S[T=
;S\T=;;P (!2T )=q[E(Y1j! 2 T )  E(Y1j! 2 S)  E(Y0j! 2 T ) + E(Y0j! 2 S)
  1
1  qE(Y1) +
1
q
E(Y0)
= argmaxS;T :S[T=
;S\T=;;P (!2T )=q[E(Y1j! 2 T )  E(Y1j! 2 S)  E(Y0j! 2 T ) + E(Y0j! 2 S)
  q
1  qE(Y1j! 2 T ) 
1  q
1  qE(Y1j! 2 S) +
q
q
E(Y0j! 2 T ) + (1  q)
q
E(Y0j! 2 S)]
= argmaxS;T :S[T=
;S\T=;;P (!2T )=q[
1  2q
1  q E(Y1j! 2 T ) +
1  2q
q
E(Y0j! 2 S)]
= argmaxS;T :S[T=
;S\T=;;P (!2T )=q[qE(Y1j! 2 T ) + (1  q)E(Y0j! 2 S)]:
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The solution to this maximization problem in fact takes a very simple form as stated in the next
proposition.
Proposition 2. The solution to
argmaxS;T :S[T=
;S\T=;;P (!2T )=q[E(Y1   Y0j! 2 T )  E(Y1   Y0j! 2 S)]
almost surely takes the form, for some , of T = f! 2 
 : Y1(!)   Y0(!) > g and S = f! 2 
 :
Y1(!)  Y0(!)  g.
Proof. We prove the result by contradiction. Suppose S and T were not of this form. Then there must
exist (possibly non-unique) disjoint sets 
0  T and 
  S of equal and positive probability such that
Y1(!
0) Y0(!0) < Y1(!) Y0(!) for all !0 2 
0 and ! 2 
. Let T 0 = (T[
)n
0 and S0 = (S[
0)n
.
Then E(Y1   Y0j! 2 T 0) E(Y1   Y0j! 2 S0) > E(Y1   Y0j! 2 T ) E(Y1   Y0j! 2 S) and thus S and T
would not be the solution to argmaxS;T :S[T=
;S\T=;;P (!2T )=q[E(Y1 Y0j! 2 T ) E(Y1 Y0j! 2 S)].
If both counterfactual outcomes were known for all individuals, then  could be obtained as the
solution to P (Y1 Y0 > ) = q and the average outcome for the population under the optimal treatment
rule of giving treatment if Y1   Y0 >  would be qE(Y1jY1   Y0 > ) + (1  q)E(Y0jY1   Y0  ). It is of
course not possible to partition individuals in this way without complete knowledge of the counterfactual
outcomes, which will in general not be available.
However, it is still possible to partition the covariate space to carry out a similar maximization. If we
let   denote the support of C the task becomes
argmaxS;T :S[T= ;S\T=;;P (C2T )=q[E(Y1   Y0j! 2 T )  E(Y1   Y0j! 2 S)]:
By arguments similar to those presented above, the solution to this takes the form of T = fc 2   :
E(Y jA = 1; c)   E(Y jA = 0; c) > kg i.e. the treatment rule is then simply give treatment to those for
whom E(Y jA = 1; c)  E(Y jA = 0; c) > k with k given as the solution toZ
1[E(Y1   Y0jC = c) > k]dP (c) = q:
In practice one must model E(Y jA = 1; C = c)  E(Y jA = 0; C = c) and estimate k.
The average outcome under this treatment rule is then given by q
Z
E(Y jA = 1; c)dP (cjC 2 T ) +
(1   q)
Z
E(Y jA = 0; c)dP (cjC =2 T ): Note that this average outcome will not in general be as high as
the average outcome under the optimal decision rule if both counterfactual outcomes were themselves
known for all individuals, in which case the average outcome would be given as above, qE(Y1jY1   Y0 >
) + (1  q)E(Y0jY1   Y0  ) where  is dened as the solution to P (Y1   Y0 > ) = q. The extent to
which the average outcome under the optimal treatment rule using the measured covariates C comes close
to that which could be obtained under complete knowledge of the counterfactual outcomes will depend
on the extent to which the covariates C are predictive of the outcome itself. Note that it is also thus of
course the case that the average outcome under the optimal treatment rule using data on the measured
covariates C will always be relative to C.
It may be of interest to compare the average outcome under this optimal treatment decision rule using
the measured covariates C to the average outcome with no one treated, E(Y jA = 0), the outcome with
100q% treated but selected randomly qE(Y jA = 1) + (1  q)E(Y jA = 0), and the average outcome with
everyone treated, E(Y jA = 1). It might also be of interest to compare the treatment e¤ect for those
treated under the optimal rule,
Z
fE(Y jA = 1; c)  E(Y jA = 0; c)gdP (cjC 2 T ), to those left untreated
by the rule
Z
fE(Y jA = 1; c)   E(Y jA = 0; c)gdP (cjC =2 T ), and also to the average treatment e¤ect
for the population E(Y jA = 1)   E(Y jA = 0). Another relevant metric may be taken as the di¤erence
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between the treatment e¤ects comparing those who are assigned treatment by the rule versus those who
are not: Z
fE(Y jA = 1; c)  E(Y jA = 0; c)gdP (cjC 2 T )
 
Z
fE(Y jA = 1; c)  E(Y jA = 0; c)gdP (cjC =2 T ):
This could be taken as a measure of e¤ect heterogeneity introduced by the optimal treatment rule for the
100q% to receive treatment. The analogous metric under treatment of a random 100q% of the population
selected for treatment would simply be 0.
Context 2: Unconstrained Treatment Subgroup Selection
Now suppose that resources are unconstrained and all could be treated who benet from treatment. The
optimal subgroup for treatment would then be
T = f! : Y1(!)  Y0(!) > 0g:
Once again, we cannot determine this subgroup as in general we will not have information on both
potential outcomes for all individuals. Instead, with covariate data on C, we would select the subgroup
to treat as those with covariates C such that the expected value of the treatment e¤ect conditional on C
was positive. Thus we would treat those with covariate values that lie in the set
T = fc 2   : E(Y jA = 1; c)  E(Y jA = 0; c) > 0g:
In practice with high dimensional C, the expectation E(Y ja; c) would have to be modeled. If we were
to follow this treatment rule, the average outcome under this rule would beZ
c2T
E(Y jA = 1; c)dP (c) +
Z
c=2T
E(Y jA = 0; c)dP (c):
Note that this average outcome will not in general be as high as the average outcome under the
optimal decision rule if both counterfactual outcomes were themselves known in which case the average
outcome would be E(Y1jY1   Y0 > 0)P (Y1   Y0 > 0) +E(Y0jY1   Y0  0)P (Y1   Y0  0). The extent to
which the average outcome under the optimal treatment rule using the measured covariates C comes close
to that which could be obtained under complete knowledge of the counterfactual outcomes will depend
on the extent to which the covariates C are predictive of the outcome itself. It is also thus of course the
case that the average outcome under the optimal treatment rule using data on the measured covariates
C will always be relative to C.
It may be of interest to compare this average outcome under the optimal treatment rule using the
measured covariates C to the average outcome with no one treated, E(Y jA = 0), and to the average
outcome with everyone treated, E(Y jA = 1). It might also be of interest to compare the treatment e¤ect
for those treated under the optimal rule
Z
fE(Y jA = 1; c)   E(Y jA = 0; c)gdP (cjC 2 T ), to those left
untreated by the rule
Z
fE(Y jA = 1; c) E(Y jA = 0; c)gdP (cjC =2 T ), and also to the average treatment
e¤ect for the population E(Y jA = 1)   E(Y jA = 0). Another relevant metric may be taken as the
di¤erence between the treatment e¤ects comparing those who are assigned treatment by the rule versus
those who are not:Z
fE(Y jA = 1; c)  E(Y jA = 0; c)gdP (cjC 2 T ) 
Z
fE(Y jA = 1; c)  E(Y jA = 0; c)gdP (cjC =2 T ):
This could be taken as a measure of e¤ect heterogeneity.
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Context 3: Unconstrained Treatment Subgroup Selection Under Costs or Side
E¤ects
Another generalization of Setting 1 that might be considered is a setting in which there is a cost constraint.
Typically this will require the investigator to only treat those with treatment e¤ect greater than some
threshold (c) that relies on the covariate value c. If all counterfactuals were known, we would use
individual-level treatment e¤ect Y1(!)  Y0(!), and we will show that this can be replaced by E(Y jA =
1; c) E(Y jA = 0; c) in the realistic setting where only one counterfactual is observed for each individual.
To formalize our discussion, we wish to estimate the solution to
Maximize
Z
c2T
E(Y jA = 1; c)dP (c) +
Z
c62T
E(Y jA = 0; c)dP (c)
subject to
Z
c2T
Cost(c)dP (c)  Cost Constraint;
where Cost() is pre-dened positive function giving the cost of treating someone in covariate strata
and Cost Constraint is the pre-dened constraint. The results in this section easily generalize to the
case where Cost(c) can equal zero, but we omit this case for simplicity. If b = E[Cost(C)] is less than
Cost Constraint then the constraint is not active and we revert to Context 2. Otherwise the T maximizing
the above objective takes the following form.
Proposition 3. If b is nite and greater than Cost Constraint, then the T maximizing the objective
function above takes the form, f! 2 
 : E(Y jA = 0; c)   E(Y jA = 0; c) > kCost(c)g, where k is the
solution to Z
1 [E(Y1   Y0jC = c) > kCost(c)] Cost(c)dP (c) = Cost Constraint :
Proof. Let Pc denote the probability measure with density dPcdP (c) = Cost(c)=b. Let
~Y = bY=Cost(C),
where we note that ~Y is a deterministic function of Y conditional on C = c so that bEP (Y jA =
a; c)=Cost(c) is equal to EP ( ~Y jA = a; c). We can write the mean outcome under the optimal rule
as Z
c2T
E( ~Y jA = 1; c)dPc(c) +
Z
c62T
E( ~Y jA = 0; c)dPc(c):
The cost constraint rewrites as Pc(C 2 T )  (Cost Constraint)=b. We are now in Context 1, so maximiz-
ing T takes the form f! 2 
 : E( ~Y jA = 0; c)  E( ~Y jA = 0; c) > ~kg, where ~k is the solution toZ
1
h
E( ~Y jA = 1; c)  E( ~Y jA = 0; c) > ~k
i
dPc(c) = (Cost Constraint)=b
Multiplying both sides by b, using the denition of ~Y , and letting k = ~k=b gives the result.
It may be of interest to compare this average outcome under the optimal treatment rule to the
average outcome with no one treated, E(Y jA = 0), and to the average outcome with everyone treated,
E(Y jA = 1). It might also be of interest to compare the treatment e¤ect for those treated under the
optimal rule,
Z
fE(Y jA = 1; c)   E(Y jA = 0; c)gdP (cjC 2 T ), to those left untreated by the ruleZ
fE(Y jA = 1; c)   E(Y jA = 0; c)gdP (cjC =2 T ), and also to the average treatment e¤ect for the
population E(Y jA = 1)  E(Y jA = 0).
Context 4: Treatment Subgroup Selection to Maximize Treatment E¤ect Het-
erogeneity
In examining subgroup analyses reported in the literature one is sometimes under the impression that
a central goal is to nd a subgroup division that maximizes e¤ect heterogeneity across the subgroups.
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While it is not clear that this goal is of principal policy importance, it can be carried out using a set of
measured covariates C. The task could then be stated as nding a partition of individuals into sets T
and S to maximize treatment e¤ect heterogeneity when comparing the treatment e¤ects among those in
T versus S. The problem could thus formally be stated as
argmaxS;T :S[T=
;S\T=;[E(Y1   Y0j! 2 T )  E(Y1   Y0j! 2 S)]:
The solution to this maximization problems takes a relatively simple form as in the next Proposition.
Proposition 4. The solution to
argmaxS;T :S[T=
;S\T=;[E(Y1   Y0j! 2 T )  E(Y1   Y0j! 2 S)]
takes the form, for some , of T = f! 2 
 : Y1(!)  Y0(!) > g and S = f! 2 
 : Y1(!)  Y0(!)  g.
Proof. The proof is similar to that of Proposition 2 above.
If we let V = Y1   Y0 and let p(v) denote the density of V . To determine , we wish to choose  to
maximize E(Y1   Y0jY1   Y0 > )  E(Y1   Y0jY1   Y0  ) or equivalently,Z 1

vp(v)dv=
Z 1

p(v)dv  
Z 
 1
vp(v)dv=
Z 
 1
p(v)dv:
Di¤erentiating with respect to  we obtain:Z 1

p(v)dv[vp(v)]v=1v=  
Z 1

vp(v)dv[p(v)]v=1v=
[
Z 1

p(v)dv]2
 
Z 
 1
p(v)dv[vp(v)]v=v= 1  
Z 
 1
vp(v)dv[p(v)]v=v= 1
[
Z 
 1
p(v)dv]2
Setting this equal to 0 and solving for  gives
[
Z 
 1
p(v)dv]2f
Z 1

p(v)dv[vp(v)]v=1v=  
Z 1

vp(v)dv[p(v)]v=1v= g   [
Z 1

p(v)dv]2f
Z 
 1
p(v)dv[vp(v)]v=v= 1
 
Z 
 1
vp(v)dv[p(v)]v=v= 1g = 0
P (V  )2 f p()P (V > ) + p()
Z 1

vp(v)dvg+ P (V > )2 f p()P (V  ) + p()
Z 
 1
vp(v)dvg = 0
P (V  )2 f P (V > ) +
Z 1

vp(v)dvg+ P (V > )2 f P (V  ) +
Z 
 1
vp(v)dvg = 0:
The solution to the equation gives  which could be obtained numerically.
The treatment rule that maximizes e¤ect heterogeneity is then either T = f! 2 
 : Y1(!) Y0(!)  g
or T = f! 2 
 : Y1(!)   Y0(!) > g. The maximum treatment e¤ect heterogeneity that can thus be
obtained comparing two subgroups that partition all individuals is thus E(Y1 Y0jY1 Y0 > ) E(Y1 
Y0jY1   Y0  ).
It is of course not possible to partition individuals in this manner without complete knowledge of the
counterfactual outcomes. However, it is still possible to carry out a similar partitioning using measured
covariates C. If we let   denote the support of C, the task becomes
argmaxS;T :S[T= ;S\T=;[E(Y1   Y0jC 2 T )  E(Y1   Y0jC 2 S)]:
By arguments similar to those presented above, the sets S and T are then given by T = fc 2   : E(Y jA =
1; c)   E(Y jA = 0; c) > kg and S = fc 2   : E(Y jA = 1; c)   E(Y jA = 0; c)  kg for some k, and once
again k could be solved for numerically.
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The e¤ect heterogeneity under this treatment rule for maximizing e¤ect heterogeneity with measured
covariates C is then given by:Z
fE(Y jA = 1; c)  E(Y jA = 0; c)gdP (cjC 2 T ) 
Z
fE(Y jA = 1; c)  E(Y jA = 0; c)gdP (cjC =2 T ):
Note that this measure of e¤ect heterogeneity will not in general be as high as the maximum e¤ect
heterogeneity if both counterfactual outcomes for all individuals were known, which was given above as
E(Y1 Y0jY1 Y0  ) E(Y1 Y0jY1 Y0 < ). The extent to which the maximum e¤ect heterogeneity
under the treatment rule using the measured covariates C comes close to the maximum which can be
obtained under complete knowledge of the counterfactual outcomes will depend on the extent to which
the covariates C are predictive of the outcome itself. Note that it is also thus of course the case that
the maximum e¤ect heterogeneity under the treatment rule using data on the measured covariates C will
always be relative to C. It might also be of interest to compare the treatment e¤ect for those treated
under the maximizing rule,
Z
fE(Y jA = 1; c)   E(Y jA = 0; c)gdP (cjC 2 T ), to those left untreated by
the rule
Z
fE(Y jA = 1; c) E(Y jA = 0; c)gdP (cjC =2 T ), and also to the average treatment e¤ect for the
population E(Y jA = 1)  E(Y jA = 0).
If using the treatment rule that maximizes e¤ect heterogeneity, one can also estimate the average
outcome under this rule asZ
c2T
E(Y jA = 1; c)dP (c) +
Z
c=2T
E(Y jA = 0; c)dP (c):
One could compare this to the average outcome with no one treated, E(Y jA = 0), and the average
outcome with everyone treated, E(Y jA = 1). Note, however, this average outcome under the treatment
rule that maximizes e¤ect heterogeneity will in general be lower than the average outcome under the
treatment rule that maximizes the average outcome itself as discussed in Context 2. It is thus not clear
that this treatment rule that maximizes e¤ect heterogeneity is of particular use in policy-making, unlike
contexts 1, 2 and 3 above.
Further Comments on Observational Studies
The above approaches and results for randomized treatment A apply also to observational studies in which
the covariates C su¢ ce to control for confounding of the e¤ect of A on Y but, when reference is made
to the average outcome when no one is treated, E(Y jA = 0) must be replaced by
Z
E(Y jA = 0; c)dP (c);
when reference is made to the average outcome when everyone is treated, E(Y jA = 1) must be replaced
by
Z
E(Y jA = 1; c)dP (c); and when reference is made to the average treatment e¤ect for the population
E(Y jA = 1)  E(Y jA = 0) must be replaced by
Z
E(Y jA = 1; c)dP (c) 
Z
E(Y jA = 0; c)dP (c).
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B. Statistical Estimation
Supose we observe an i.i.d. sample (C1; A1; Y1); : : : ; (Cn; An; Yn) of observations generated according to
a randomized trial. We now consider estimation of the parameter from Context 2 in this setting. All of
these estimation problems rely on the user having an estimate of the conditional average treatment e¤ect
(CATE), i.e. the function mapping rom a covariate c to E[Y jA = 1; c]   E[Y jA = 0; c]. We therefore
start by presenting an estimation procedure for this quantity, and then proceed to give an overview of
estimation for Contexts 1 and 2. A specic estimation procedure for Contexts 1 and 2 can be found in
the eAppendix.
Estimation of the Conditional Average Treatment E¤ect
We frame the estimation of the CATE as a regression problem, which thereby enables both the use
of classical linear regression approaches and also any machine learning algorithm which is designed to
estimate a conditional mean function.
For any triplet of observations (c; a; y) and a given function f mapping from (a; c) to the real line,
dene the pseudo-outcome
~y =
2a  1
P (A = ajC = c) [y   f(a; c)] + f(1; c)  f(0; c);
where we recall that the probability of treatment given covariates is known in our randomized trial setting.
We use ~Y1; : : : ; ~Yn to denote the corresponding random variable for our trial participants and ~Y to denote
the general random variable corresponding to (C;A; Y ). We will provide guidance on the selection of f
at the end of this section. Observe that
E
h
~Y
C = ci = E[Y jA = 1; c]  E[Y jA = 0; c]:
This justies the following estimation procedure for the CATE function:
1. Dene pseudo-observations ~Y1; : : : ; ~Yn.
2. Regress ( ~Y1; : : : ; ~Yn) against (C1; : : : ; Cn) using a preferred regression algorithm.
Suppose for simplicity than one restricts oneself to least squares regression techniques for the latter step
(possibly subject to some complexity penalty). The class of such techniques is far richer than the classical
linear regression techniques: for example, generalized additive models, kernel smoothers, and smoothing
splines can all be t using this criterion (Hastie et al., 2002). The estimate for the CATE resulting from
the above will typically provide a mean-square consistent estimate if the regression algorithm is correctly
specied, and otherwise one can still measure the quality of a given estimate using mean-squared error
(MSE). Furthermore, if one has two correctly specied regression algorithms so that both have MSE
converging to zero with sample size, then typically the MSE of the simplerestimator decays at a faster
rate. As a simple example, a correctly specied univariate linear regression will typically have smaller
MSE than a correctly specied random forest regression in nite samples.
Committing to a single regression algorithm in the second step above is therefore unadvisable: ideally
one wants to select the simplest estimator which is (nearly) correctly specied so that the MSE is small for
the nite sample, but doing so a priori is not generally possible. To overcome this di¢ culty, we propose
the use of the ensemble algorithm known as super-learning (van der Laan, 2007). This algorithm allows the
user to input a library of candidate regression algorithms and outputs the t from a convex combination
of the candidate algorithms. This convex combination is selected to minimize the cross-validated MSE
between ~Y and the t. The super-learner algorithm is optimal in the sense that the cross-validated MSE
of the resulting t is at least as good as the cross-validated MSE of the best algorithm in the library (up
to a small remainder term). The usefulness of this nite sample result has been repeatedly supported
by simulations in the literature (cf. Polley and van der Laan, 2010; van der Laan and Rose, 2011). See
Luedtke and van der Laan (2014) for theoretical foundations and simulation results specic to the CATE.
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We conclude by discussing the selection of the function f . As the described method is valid for any
xed function f , one can set f equal to the constant function zero so that the pseudo-outcome takes on
a simple form. Though appealing for its simplicity, this choice of f will generally yield a suboptimal t
of the CATE. Given that it is typically easier to t a regression when the conditional variance of the
outcome given covariates is smaller, one may wish to choose f to make this quantity small. The choice
of f which minimizes this quantity is given by f(a; c) = E[Y ja; c]. In practice E[Y ja; c] is not known,
but typically substituting an estimate E^[Y ja; c] will perform better than choosing f equal to zero (see
Luedtke and van der Laan (2014) for a deeper discussion, and a double robustness based justication for
selecting f in this way that will prove useful in observational studies).
Estimates for Contexts 1 and 2
In the eAppendix we provide estimates for the parameters arising in Contexts 1 and 2 given an i.i.d.
sample (C1; A1; Y1); : : : ; (Cn; An; Yn) generated from a randomized trial. We propose using the cross-
validated targeted minimum loss-based estimation (CV-TMLE) framework to estimate these quantities.
This framework allows the user to provide initial estimates of the outcome regression E[Y ja; c] and the
CATE, where we do not require that the CATE estimate is equal to the di¤erence of outcome regressions
at A = 1 and A = 0. We advise using the super-learner methodology for the CATE discussed in the
previous section, and a standard regression-based super-learner for the outcome regression, regressing Y
against treatment and covariates.
At this point one might be tempted to use as estimate the substitution estimator
1
n
nX
i=1
1

\CATE(Ci) > n

E^[Y j1; Ci]  E^[Y j0; Ci]

;
where n = 0 for Context 1 and n is the cuto¤ estimated from the data for Context 2. Unfortunately,
this estimate will tend to be too biased for the parameter of interest, thereby making root-n rate inference
impossible. For intuition we will rst discuss the non-cross-validated TMLE procedure, and then discuss
how the CV-TMLE procedure di¤ers. The TMLE procedure confronts this challenge by uctuating the
initial outcome regression estimate E^[Y ja; c] with a univariate submodel selected to reduce the bias of the
above substitution estimator for the parameter of interest. Though a thorough description of the selected
submodel is beyond the scope of this manuscript, we invite readers to explore Luedtke and van der Laan
(2015) and van der Laan and Luedtke (2014) for the justication of the submodels used in Contexts 1
and 2, respectively. Given a uctuated outcome regression estimate E^[Y ja; c], one can then use the less
biased substitution estimator
1
n
nX
i=1
1

\CATE(Ci) > n

E^[Y j1; Ci]  E^[Y j0; Ci]

Though one can establish regularity conditions under which the bias is asymptotically negligible, it is
di¢ cult to establish reasonable conditions exerting control over the nite sample bias of this estimator,
especially in Context 2 where we are attempting to make inference on a quantity that the true CATE
maximizes over. Though we may use a di¤erent criteria function to estimate the CATE, this estimator
will still be prone to positive bias in nite samples. This positive bias manifests itself similarly to the
negative bias that results when one attempts to estimate the squared error between an outcome Y and
estimated regression function E^[Y jX] using the empirical squared error.
A natural solution to this nite sample bias issue is to use cross-validation. In the appendix we
present a cross-validated form of the TMLE algorithm for which this bias should not appear. Under a
mild consistency condition, our nal estimator  ^ of the parameters  from Context 1 satises the identity
 ^   1
n
nX
i=1
D0(Oi)+
1
10
10X
v=1
E
h
I(\CATEv(C) > 0)  I(E[Y j1; C]  E[Y j0; C] > 0)

(E[Y j1; C]  E[Y j0; C])
i
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for a xed function D0, where each \CATEv is an estimate of the CATE t on 9/10 of the data and the
approximation holds up to a remainder term that shrinks to zero faster than n 1=2 in probability. If
the second term on the right is negligible, then we can develop standard Wald-type condence intervals
for the parameter of interest using the central limit theorem. Theorem 8 in Luedtke and van der Laan
(2016) shows that the second term on the right is indeed su¢ ciently small under a variety of assumptions
on the rate of convergence of the estimate of the CATE, one of which is a condition on its MSE. A
similar expansion holds for Context 2, though we omit it for brevity (see Luedtke and van der Laan
(2015) for details). Finally, we observe that the second term on the right-hand side above is nonpositive.
Hence, even if this term fails to be su¢ ciently small to be asymptotically negligible, our estimator for
the parameter of interest will at worst be negatively biased. One can further show that this implies to
establish the asymptotic validity of the lower bound of our condence interval regardless of the quality
of our estimate of the CATE.
Super-Learner for the Conditional Average Treatment E¤ect
The super-learner algorithm for this estimation problem is given below. For simplicity we use ten-fold
cross-validation and assume that the sample size n is a multiple of ten. We suppose that the user has m
candidate regression algorithms.
1. Dene pseudo-observations ~Y1; : : : ; ~Yn.
2. For v in f1; : : : ; 10g:
(a) For ` in f1; : : : ;mg:
 Fit candidate algorithm ` on observations

(Ci; ~Yi) : i 62
n
(v 1)n
10 + 1; : : : ;
vn
10
o
to gener-
ate the regression function estimate that takes as input c and outputs E^`v[ ~Y jc].
(b) For i in
n
(v 1)n
10 + 1; : : : ;
vn
10
o
, deneXCVi to be them-length column vector

E^`v[ ~Y jci] : ` = 1; : : : ;m

.
3. Choose n be the convex m-length row vector minimizing 1n
Pn
i=1

~Yi   nXCVi
2
.
4. For ` in f1; : : : ;mg:
 Fit the candidates ` on all of the observations, yielding a function which takes as input c and
outputs E^`[ ~Y jc].
5. Return the function b^ dened by b^(c) = nX(c), whereX(c) is the column vector

E^`[ ~Y jc] : ` = 1; : : : ;m

.
Estimator for Contexts 1 and 2
We now present a cross-validated targeted minimum loss-based estimator (CV-TMLE) for Contexts 1
and 2. We omit the derivation of this estimator from this work for brevity, and instead refer the reader
to references given in the main text for the derivation of CV-TMLEs for a nearly identical parameters
as in Contexts 1 and 2. We assume that the outcome Y is bounded, and without loss of generality we
assume that the lower bound is 0 and the upper bound is 1.
For simplicity, we use ten-fold cross-validation and assume that the sample size n is a multiple of ten.
For each v = 1; : : : ; 10, we let Tv denote the observations (Ci; Ai; Yi) with indices i 62
n
(v 1)n
10 + 1; : : : ;
vn
10
o
,
i.e. the observations included in the training sample for a given cross-validation split. We also let v(i)
denote the v such that i 62
n
(v 1)n
10 + 1; : : : ;
vn
10
o
, i.e. the cross-validation index for which i is not in the
training sample.
1. For v in f1; : : : ; 10g:
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(a) Obtain an estimate E^v[Y j] of the function mapping from (a; c) to E[Y ja; c] using observations
in Tv.
(b) Obtain an estimate b^v of the CATE function using observations in Tv.
Note: b^v(c) need not equal E^[Y jA = 1; c]  E^[Y jA = 0; c].
2. Let n = 0 in Context 2, and in Context 1 let n be the positive part of the smallest solution in 
to
1
n
nX
i=1
1(b^v(i)(c) > )  q:
3. Let n be the slope estimate in an intercept-free logistic regression with outcome (Yi : i = 1; : : : ; n),
covariate

2Ai 1
P (AijCi) : i = 1; : : : ; n

, o¤set

logit E^v(i)[Y jAi; Ci] : i = 1; : : : ; n

, and observation weights
1
n
b^v(i)(Ci) > n
o
: i = 1; : : : ; n

.
Note: The glm function in R will run a logistic regression on any outcome bounded in [0; 1].
4. For each v in f1; : : : ; 10g and any (a; c), let Qv(a; c) = logit 1
h
logit

E^v[Y ja; c]

+ n
2a 1
P (ajc)
i
repre-
sent the uctuated estimate of E[Y ja; c].
5. Let  ^ = 1n
Pn
i=1 1(b^v(i)(Ci) > n)
h
Qv(i)(1; Ci)  Qv(i)(0; Ci)
i
.
6. Let Di = 2Ai 1P (AijCi)
h
Yi   Qv(i)(Ai; Ci)
i
+ Qv(i)(1; Ci)  Qv(i)(0; Ci)   ^.
7. Let
^2 =
1
n
nX
i=1
h
1(b^v(i)(Ci) > n) [Di   n] + nq
i2
;
where we take q = 1 in Context 2.
8. Return the point estimate  ^ and 95% condence interval  ^  1:96 ^p
n
.
C. Software
To be completed.
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